



## Pharmacogenomics of Oncology Therapies

Guest Editor:

**Dr. Alan L. Myers**

Department of Diagnostic and  
Biomedical Sciences, University  
of Texas Health Science Center  
Houston, Houston, TX, USA

Deadline for manuscript  
submissions:

**closed (1 November 2021)**

### Message from the Guest Editor

Background: Precision medicine in the form of pharmacogenomics (PGx) is an ever-increasing area of practice in the oncology care setting. Many examples exist as to how genetic polymorphisms influence a drug's effect by altering its PK-PD. However for cancer therapies, which are often limited by a narrow therapeutic index and inter-individual variation in response, a better understanding of how genetic factors influence drug metabolism/transport and consequent treatment outcomes is still critically needed.

Aim and Scope: The aim of this Special Issue is to provide recent trends, updates, and progress on how PGx, on both the basic science and clinical level, is improving cancer care.

What kind of papers we are soliciting: We are inviting the submission of original articles to this Special Issue of *JPM* that covers the whole spectrum of PGx of oncology therapies and adjuvant drugs used in the cancer care setting – from basic science to case reports and full clinical studies, and relevant review articles.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)